Skip to main content

NimbleGen, LICR, Iceland Genomics Get $1.7M NCI Grant to Map Cancer Pathways

NEW YORK, Oct. 12 (GenomeWeb News) - The National Cancer Institute has awarded NimbleGen, the Ludwig Institute for Cancer Research, and Iceland Genomics a $1.7 million, 4-year grant to map regulatory pathways in cancer, NimbleGen said today.

Specifically, NimbleGen and the University of San Diego branch of the LICR will co-develop next generation chromatin immunoprecipitation (ChIP)-on-chip methodologies to map transcription factor binding sites throughout the human genome. Iceland Genomics will provide samples from its clinical cancer database to be screened for TF binding using the new methodology.

It is not the first time the three have worked together. NimbleGen and LICR worked together on ChIP-on-chip technologies within the ENCODE consortium, while Iceland Genomics helped NimbleGen open its Reykjavik-based subsidiary in that country in 2002.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.